287 related articles for article (PubMed ID: 14769151)
1. Novel growth and death related interferon-stimulated genes (ISGs) in melanoma: greater potency of IFN-beta compared with IFN-alpha2.
Leaman DW; Chawla-Sarkar M; Jacobs B; Vyas K; Sun Y; Ozdemir A; Yi T; Williams BR; Borden EC
J Interferon Cytokine Res; 2003 Dec; 23(12):745-56. PubMed ID: 14769151
[TBL] [Abstract][Full Text] [Related]
2. Preferential induction of apoptosis by interferon (IFN)-beta compared with IFN-alpha2: correlation with TRAIL/Apo2L induction in melanoma cell lines.
Chawla-Sarkar M; Leaman DW; Borden EC
Clin Cancer Res; 2001 Jun; 7(6):1821-31. PubMed ID: 11410525
[TBL] [Abstract][Full Text] [Related]
3. Expression of RASSF1A, an epigenetically silenced tumor suppressor, overcomes resistance to apoptosis induction by interferons.
Reu FJ; Leaman DW; Maitra RR; Bae SI; Cherkassky L; Fox MW; Rempinski DR; Beaulieu N; MacLeod AR; Borden EC
Cancer Res; 2006 Mar; 66(5):2785-93. PubMed ID: 16510600
[TBL] [Abstract][Full Text] [Related]
4. IFN-beta pretreatment sensitizes human melanoma cells to TRAIL/Apo2 ligand-induced apoptosis.
Chawla-Sarkar M; Leaman DW; Jacobs BS; Borden EC
J Immunol; 2002 Jul; 169(2):847-55. PubMed ID: 12097388
[TBL] [Abstract][Full Text] [Related]
5. Novel interferon-beta-induced gene expression in peripheral blood cells.
Rani MR; Shrock J; Appachi S; Rudick RA; Williams BR; Ransohoff RM
J Leukoc Biol; 2007 Nov; 82(5):1353-60. PubMed ID: 17709400
[TBL] [Abstract][Full Text] [Related]
6. Identification of X-linked inhibitor of apoptosis-associated factor-1 as an interferon-stimulated gene that augments TRAIL Apo2L-induced apoptosis.
Leaman DW; Chawla-Sarkar M; Vyas K; Reheman M; Tamai K; Toji S; Borden EC
J Biol Chem; 2002 Aug; 277(32):28504-11. PubMed ID: 12029096
[TBL] [Abstract][Full Text] [Related]
7. TRAIL is a key target in S-phase slowing-dependent apoptosis induced by interferon-beta in cervical carcinoma cells.
Vannucchi S; Chiantore MV; Fiorucci G; Percario ZA; Leone S; Affabris E; Romeo G
Oncogene; 2005 Apr; 24(15):2536-46. PubMed ID: 15735750
[TBL] [Abstract][Full Text] [Related]
8. Resistance to interferons in melanoma cells does not correlate with the expression or activation of signal transducer and activator of transcription 1 (Stat1).
Chawla-Sarkar M; Leaman DW; Jacobs BS; Tuthill RJ; Chatterjee-Kishore M; Stark GR; Borden EC
J Interferon Cytokine Res; 2002 May; 22(5):603-13. PubMed ID: 12060499
[TBL] [Abstract][Full Text] [Related]
9. Overcoming resistance to interferon-induced apoptosis of renal carcinoma and melanoma cells by DNA demethylation.
Reu FJ; Bae SI; Cherkassky L; Leaman DW; Lindner D; Beaulieu N; MacLeod AR; Borden EC
J Clin Oncol; 2006 Aug; 24(23):3771-9. PubMed ID: 16801630
[TBL] [Abstract][Full Text] [Related]
10. Requirement of catalytically active Tyk2 and accessory signals for the induction of TRAIL mRNA by IFN-beta.
Rani MR; Pandalai S; Shrock J; Almasan A; Ransohoff RM
J Interferon Cytokine Res; 2007 Sep; 27(9):767-79. PubMed ID: 17892398
[TBL] [Abstract][Full Text] [Related]
11. Stat1-dependent induction of tumor necrosis factor-related apoptosis-inducing ligand and the cell-surface death signaling pathway by interferon beta in human cancer cells.
Choi EA; Lei H; Maron DJ; Wilson JM; Barsoum J; Fraker DL; El-Deiry WS; Spitz FR
Cancer Res; 2003 Sep; 63(17):5299-307. PubMed ID: 14500361
[TBL] [Abstract][Full Text] [Related]
12. Induction of a TRAIL-mediated suicide program by interferon alpha in primary effusion lymphoma.
Toomey NL; Deyev VV; Wood C; Boise LH; Scott D; Liu LH; Cabral L; Podack ER; Barber GN; Harrington WJ
Oncogene; 2001 Oct; 20(48):7029-40. PubMed ID: 11704827
[TBL] [Abstract][Full Text] [Related]
13. Interferon (IFN)-beta induces apoptotic cell death in DHL-4 diffuse large B cell lymphoma cells through tumor necrosis factor-related apoptosis-inducing ligand (TRAIL).
Oehadian A; Koide N; Mu MM; Hassan F; Islam S; Yoshida T; Yokochi T
Cancer Lett; 2005 Jul; 225(1):85-92. PubMed ID: 15922860
[TBL] [Abstract][Full Text] [Related]
14. Type I interferons (IFNs) regulate tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) expression on human T cells: A novel mechanism for the antitumor effects of type I IFNs.
Kayagaki N; Yamaguchi N; Nakayama M; Eto H; Okumura K; Yagita H
J Exp Med; 1999 May; 189(9):1451-60. PubMed ID: 10224285
[TBL] [Abstract][Full Text] [Related]
15. Biological markers of interferon-beta therapy: comparison among interferon-stimulated genes MxA, TRAIL and XAF-1.
Gilli F; Marnetto F; Caldano M; Sala A; Malucchi S; Capobianco M; Bertolotto A
Mult Scler; 2006 Feb; 12(1):47-57. PubMed ID: 16459719
[TBL] [Abstract][Full Text] [Related]
16. Reversal of methylation silencing of Apo2L/TRAIL receptor 1 (DR4) expression overcomes resistance of SK-MEL-3 and SK-MEL-28 melanoma cells to interferons (IFNs) or Apo2L/TRAIL.
Bae SI; Cheriyath V; Jacobs BS; Reu FJ; Borden EC
Oncogene; 2008 Jan; 27(4):490-8. PubMed ID: 17653094
[TBL] [Abstract][Full Text] [Related]
17. Requirement of c-Jun NH2-terminal kinase activation in interferon-alpha-induced apoptosis through upregulation of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) in Daudi B lymphoma cells.
Yanase N; Hata K; Shimo K; Hayashida M; Evers BM; Mizuguchi J
Exp Cell Res; 2005 Oct; 310(1):10-21. PubMed ID: 16099454
[TBL] [Abstract][Full Text] [Related]
18. Identification of genes differentially regulated by interferon alpha, beta, or gamma using oligonucleotide arrays.
Der SD; Zhou A; Williams BR; Silverman RH
Proc Natl Acad Sci U S A; 1998 Dec; 95(26):15623-8. PubMed ID: 9861020
[TBL] [Abstract][Full Text] [Related]
19. Absence of gene mutation in TRAIL receptor 1 (TRAIL-R1) and TRAIL receptor 2 (TRAIL-R2) in chronic myelogenous leukemia and myelodysplastic syndrome, and analysis of mRNA Expressions of TRAIL and TRAIL-related genes in chronic myelogenous leukemia.
Liu LG; Tanaka H; Ito K; Ito T; Sultana TA; Kyo T; Kimura A
Acta Haematol; 2005; 113(2):113-23. PubMed ID: 15802890
[TBL] [Abstract][Full Text] [Related]
20. Involvement of TRAIL/TRAIL-R interaction in IFN-alpha-induced apoptosis of Daudi B lymphoma cells.
Oshima K; Yanase N; Ibukiyama C; Yamashina A; Kayagaki N; Yagita H; Mizuguchi J
Cytokine; 2001 May; 14(4):193-201. PubMed ID: 11448118
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
